PSNL earnings call summary

Prepared Highlights

• Q1 2026 clinical test volume exceeded 7,800 tests, representing 26% sequential growth over Q4 2025 and 258% year-over-year increase (CEO)
• Total Q1 revenue $15.5 million, reflecting intentional shift from lower-margin legacy enterprise to high-value strategic testing (CEO, CFO)
• Q1 strategic revenue (clinical + biopharma MRD) $4.5 million (CEO)
• Clinical revenue Q1 $1.4 million vs $0.3 million in Q1 2025, driven by breast (Nov 2025) and lung (Feb 2026) Medicare coverage (CFO)
• Biopharma MRD revenue Q1 $3.1 million; full-year target $20–$21 million with majority expected H2 as large trials ramp (CFO)
• Biopharma testing services Q1 $11.2 million vs $13.6 million YoY, entirely due to Moderna Phase 3 trial enrollment completion; baseline $2M–$3M/quarter from Moderna rest of year (CFO)
• Gross margin Q1 1.8% vs 35% prior year, intentionally compressed by ~2,000 bps from unreimbursed test costs; lowest expected in Q1–Q2, improving after IO coverage (CFO)
• Operating expenses Q1 $32.4 million (R&D $14.5M, SG&A $17.9M) vs $24.9 million YoY, driven by commercial scale-up, studies, and technology investment (CFO)
• Net loss Q1 $30.0 million vs $15.8 million YoY; cash used Q1 ~$28 million (incl. ~$5M incentive comp) (CFO)
• Cash and short-term investments $233.2 million at quarter end, no debt (CFO)
• Backlog of contracted biopharma MRD projects growing; funnel expanding (CFO)

Official Guidance (full-year 2026, unchanged from prior):

• Total revenue $78–$80 million (26% growth at midpoint vs 2025 ex-non-strategic/license)
• Strategic revenue $30–$32 million (more than double YoY)
• Clinical revenue $10–$11 million (breast & lung surveillance only)
• Biopharma tests & services $55–$56 million (of which MRD $20–$21 million)
• Population sequencing + enterprise ~$13 million
• Gross margin 15%–20% (Q1/Q2 lowest)
• Net loss ~$105 million
• Cash usage ~$100 million

Mgmt Quotes:

• “Physicians trust NeXT Personal, our clinical test volumes are accelerating, and the broader medical community is validating our roadmap.” — CEO
• “We are not just talking about the potential of NeXT Personal anymore; we are actively seeing it translate into clinical volume, biopharma adoption, and a robust data set.” — CEO
• “The margin dynamic is driven by the strong growth in NeXT Personal test volume ahead of reimbursed revenue, and our goal of gaining market share now.” — CFO
• “We are securing positions and volume now so when coverage decisions like the recent wins in breast and lung cancer come online, that volume run rate converts to higher-margin revenue.” — CFO
• “We are leading the ultrasensitive MRD market with our technology, and the proof point is our ramping clinical test volume.” — CFO

Prepared Metrics

Q&A Batch (1-5 of 5)

Q1 — Subhalaxmi T. Nambi

• Topic: 竞争态势与季度指引
• Key points:
  • 1Q临床测试量7,800，环比增长26%，符合季节性规律
  • 全年目标43,000–45,000例测试，与Tempus合作推进“有序抢地”
  • 季度内下单医生数突破1,000，现有账户留存率显著
• Mgmt stance: 看涨——策略执行到位，医生下单深度提升，竞争中以超敏能力取胜

Q2 — Mark Massaro

• Topic: 细分癌种占比、IO覆盖、ASCO数据及竞争定位
• Key points:
  • 乳腺癌约占20%，肺癌在15%–20%之间（Q1接近15%）
  • IO覆盖于8月提交，进展乐观；ASCO将公布更多结直肠癌数据及新癌种扩展
  • Tempus公开数据显示肿瘤知情测试占其MRD量90%以上
• Mgmt stance: 看涨——超敏肿瘤知情方法为医生核心需求，灵敏度是市场主导因素

Q3 — Thomas Flaten

• Topic: 毛利率指引与销售激励策略
• Key points:
  • 全年毛利率指引15%–20%，Q1略低于2%，Q2略有上升，上半年为低点
  • ASP预期上涨将推动毛利扩张并减少现金消耗
  • 不刻意限制非报销适应症销售，以维护医生关系和未来报销基础
• Mgmt stance: 中性偏乐观——低毛利阶段可控，后半年及未来年份将因报销改善而提升

Q4 — Joseph Conway

• Topic: 医生渗透规模与生物制药业务可见性
• Key points:
  • Q1内有超过1,000名医生下单（非累计），大部分有MRD使用经验
  • 生物制药MRD积压持续增长，漏斗机会强劲；年中已牢固确认全年$20M–$21M MRD收入指引
  • 部分前瞻性项目周期超12个月，提供更长可见性
• Mgmt stance: 看涨——积压和合同确认程度高，对实现全年指引有信心

Q5 — Daniel Gregory Brennan

• Topic: 超敏方法市场接受度与MolDX流程
• Key points:
  • 临床认知转向：超敏被认为是“必须”而非“锦上添花”；ASCO将提供结直肠癌等数据强化
  • 全年测试量指引维持43,000–45,000，Q1进展良好
  • MolDX回复周期60天，往返次数视适应症而定；乳腺癌流程因首次审评耗时较长
• Mgmt stance: 看涨——数据说服力强，市场兴趣明确，对监管流程进展保持信心

Q&A Batch (6-6 of 6)

Q6 — William Bonello

• Topic: 测试组合中报销适应症比例及销售渠道策略
• Key points:
  • 约35%的测试来自报销适应症；公司战略上更积极推动医生使用乳腺癌或肺癌测试，但不强制医生只送检报销适应症样本。
  • 内部销售团队销量环比未下降（持平），Q1通常季节性较慢；总销量环比增长26%，其中Tempus渠道占80%以上。
  • 公司不与Tempus在销售现场竞争，而是协同合作；Tempus提供深度基础设施（EMR链接、门户等）和一站式服务。
• Mgmt stance: 中性偏积极——强调总销量增长和渠道协同，不刻意区分报销与非报销适应症，但持续推动报销范围扩大。